Nektar Therapeutics

NasdaqCM:NKTR Stock Report

Market Cap: US$2.1b

Nektar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:NKTR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 May 26SellUS$13,036Jonathan ZalevskyIndividual199US$65.51
19 May 26SellUS$29,086Howard RobinIndividual444US$65.51
18 Feb 26SellUS$30,879Howard RobinIndividual423US$73.00
18 Feb 26SellUS$13,140Jonathan ZalevskyIndividual180US$73.00
25 Nov 25SellUS$119,796Howard RobinIndividual2,207US$54.28
25 Nov 25SellUS$34,196Mark WilsonIndividual630US$54.28
25 Nov 25SellUS$62,802Jonathan ZalevskyIndividual1,157US$54.28
19 Aug 25SellUS$41,826Howard RobinIndividual1,573US$26.59
19 Aug 25SellUS$17,975Mark WilsonIndividual676US$26.59
19 Aug 25SellUS$19,278Jonathan ZalevskyIndividual725US$26.59

Insider Trading Volume

Insider Buying: NKTR insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of NKTR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders156,6700.464%
Hedge Funds4,518,77313.4%
General Public6,595,51419.5%
Institutions22,515,07566.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 172.3%.

Top Shareholders

Top 25 shareholders own 58.39% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.7%
FMR LLC
4,303,156US$262.1m4,160%0.01%
7.58%
BVF Partners L.P.
2,559,595US$155.9m64.1%4.24%
5.8%
Two Seas Capital LP
1,959,178US$119.4m163%4.55%
3.54%
Vanguard Capital Management, LLC
1,197,055US$72.9m0%no data
2.75%
Two Sigma Investments, LP
930,741US$56.7m96.8%0.04%
2.18%
Prosight Management, LP
735,000US$44.8m32.5%8.21%
2.05%
BlackRock, Inc.
692,650US$42.2m7.29%no data
1.93%
Emerald Advisers, LLC
650,710US$39.6m2.08%0.59%
1.89%
Morgan Stanley
637,935US$38.9m13.1%no data
1.71%
Armistice Capital LLC
578,000US$35.2m-3.02%0.94%
1.52%
Citadel Advisors LLC
513,531US$31.3m65.8%0.02%
1.51%
Sofinnova Investments, Inc.
509,546US$31.0m16.2%1.52%
1.26%
Invesco Ltd.
425,341US$25.9m3.91%0.01%
1.23%
Woodline Partners LP
415,335US$25.3m299%0.08%
1.2%
Lord, Abbett & Co. LLC
405,080US$24.7m0%0.07%
1.2%
Millennium Management LLC
404,277US$24.6m-11%0.01%
1.16%
Qube Research & Technologies Ltd
390,675US$23.8m20.6%0.03%
1.05%
UBS Asset Management AG
354,197US$21.6m16.6%no data
1.03%
Geode Capital Management, LLC
346,795US$21.1m36.3%no data
0.94%
Great Point Partners, LLC
316,453US$19.3m50.2%4.51%
0.84%
Vestal Point Capital, LP
285,000US$17.4m0%0.47%
0.84%
Susquehanna International Group, LLP
283,617US$17.3m-29%0.02%
0.83%
22NW, LP
281,115US$17.1m-15.1%12.0%
0.83%
PRIMECAP Management Company
279,150US$17.0m-0.36%0.01%
0.81%
OrbiMed Advisors LLC
275,000US$16.8m0%0.26%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/18 21:52
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nektar Therapeutics is covered by 31 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research